84 related articles for article (PubMed ID: 9014007)
1. Influence of glycoproteins B, C and D on the conversion of virus-to-cell attachment from heparin sensitivity to resistance.
Seck T; Koch O; Lingen M; Falke D
Acta Virol; 1996 Sep; 40(4):179-85. PubMed ID: 9014007
[TBL] [Abstract][Full Text] [Related]
2. Modified entry and syncytium formation by herpes simplex virus type 1 mutants selected for resistance to heparin inhibition.
Pertel PE; Spear PG
Virology; 1996 Dec; 226(1):22-33. PubMed ID: 8941319
[TBL] [Abstract][Full Text] [Related]
3. Kinetic analysis of glycoprotein C of herpes simplex virus types 1 and 2 binding to heparin, heparan sulfate, and complement component C3b.
Rux AH; Lou H; Lambris JD; Friedman HM; Eisenberg RJ; Cohen GH
Virology; 2002 Mar; 294(2):324-32. PubMed ID: 12009874
[TBL] [Abstract][Full Text] [Related]
4. Differences in the role of glycoprotein C of HSV-1 and HSV-2 in viral binding may contribute to serotype differences in cell tropism.
Gerber SI; Belval BJ; Herold BC
Virology; 1995 Dec; 214(1):29-39. PubMed ID: 8525631
[TBL] [Abstract][Full Text] [Related]
5. Neomycin inhibits glycoprotein C (gC)-dependent binding of herpes simplex virus type 1 to cells and also inhibits postbinding events in entry.
Herold BC; Spear PG
Virology; 1994 Aug; 203(1):166-71. PubMed ID: 8030274
[TBL] [Abstract][Full Text] [Related]
6. Identification of structural features of heparin required for inhibition of herpes simplex virus type 1 binding.
Herold BC; Gerber SI; Polonsky T; Belval BJ; Shaklee PN; Holme K
Virology; 1995 Feb; 206(2):1108-16. PubMed ID: 7856085
[TBL] [Abstract][Full Text] [Related]
7. Characterization of herpes simplex virus type 1 recombinants that express and incorporate high levels of HCV E2-gC chimeric proteins.
Kouvatsis V; Argnani R; Tsitoura E; Arsenakis M; Georgopoulou U; Mavromara P; Manservigi R
Virus Res; 2007 Jan; 123(1):40-9. PubMed ID: 16989918
[TBL] [Abstract][Full Text] [Related]
8. Characterization of glycoprotein C of HSZP strain of herpes simplex virus 1.
Oravcová I; Kúdelová M; Mlcuchová J; Matis J; Bystrická M; Westra DF; Welling-Wester S; Rajcáni J
Acta Virol; 2000 Apr; 44(2):99-108. PubMed ID: 10989701
[TBL] [Abstract][Full Text] [Related]
9. Cell-specific kinetics and efficiency of herpes simplex virus type 1 entry are determined by two distinct phases of attachment.
McClain DS; Fuller AO
Virology; 1994 Feb; 198(2):690-702. PubMed ID: 8291250
[TBL] [Abstract][Full Text] [Related]
10. Glycoproteins gIII and gp50 play dominant roles in the biphasic attachment of pseudorabies virus.
Karger A; Mettenleiter TC
Virology; 1993 Jun; 194(2):654-64. PubMed ID: 8389078
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis for resistance of herpes simplex virus type 1 mutants to the sulfated oligosaccharide inhibitor PI-88.
Ekblad M; Adamiak B; Bergefall K; Nenonen H; Roth A; Bergstrom T; Ferro V; Trybala E
Virology; 2007 Oct; 367(2):244-52. PubMed ID: 17604805
[TBL] [Abstract][Full Text] [Related]
12. Specific targeted binding of herpes simplex virus type 1 to hepatocytes via the human hepatitis B virus preS1 peptide.
Argnani R; Boccafogli L; Marconi PC; Manservigi R
Gene Ther; 2004 Jul; 11(13):1087-98. PubMed ID: 15057264
[TBL] [Abstract][Full Text] [Related]
13. Structure-function analysis of herpes simplex virus glycoprotein B with fusion-from-without activity.
Roller DG; Dollery SJ; Doyle JL; Nicola AV
Virology; 2008 Dec; 382(2):207-16. PubMed ID: 18950828
[TBL] [Abstract][Full Text] [Related]
14. Glycoprotein D homologs in herpes simplex virus type 1, pseudorabies virus, and bovine herpes virus type 1 bind directly to human HveC(nectin-1) with different affinities.
Connolly SA; Whitbeck JJ; Rux AH; Krummenacher C; van Drunen Littel-van den Hurk S; Cohen GH; Eisenberg RJ
Virology; 2001 Feb; 280(1):7-18. PubMed ID: 11162814
[TBL] [Abstract][Full Text] [Related]
15. Cellular and viral requirements for rapid endocytic entry of herpes simplex virus.
Nicola AV; Straus SE
J Virol; 2004 Jul; 78(14):7508-17. PubMed ID: 15220424
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of anise oil, dwarf-pine oil and chamomile oil against thymidine-kinase-positive and thymidine-kinase-negative herpesviruses.
Koch C; Reichling J; Kehm R; Sharaf MM; Zentgraf H; Schneele J; Schnitzler P
J Pharm Pharmacol; 2008 Nov; 60(11):1545-50. PubMed ID: 18957177
[TBL] [Abstract][Full Text] [Related]
17. Pathogenic potentials of glycoprotein C-negative syncytial mutants from rabbit T cells infected persistently with herpes simplex virus type 1.
Ishida Y; Okabe T; Azukizawa Y; Isono T; Seto A
J Med Virol; 2005 May; 76(1):89-97. PubMed ID: 15779044
[TBL] [Abstract][Full Text] [Related]
18. Cell-type dependent sensitivity of herpes simplex virus 1 mutants to plaque development inhibition by an anti-gD monoclonal antibody.
Mannini-Palenzona A; Moschella A; Costanzo F; Manservigi R; Monini P
New Microbiol; 1995 Oct; 18(4):351-8. PubMed ID: 8590387
[TBL] [Abstract][Full Text] [Related]
19. Effects of linker-insertion mutations in herpes simplex virus 1 gD on glycoprotein-induced fusion with cells expressing HVEM or nectin-1.
Jogger CR; Montgomery RI; Spear PG
Virology; 2004 Jan; 318(1):318-26. PubMed ID: 14972557
[TBL] [Abstract][Full Text] [Related]
20. An alpha-helical domain within the carboxyl terminus of herpes simplex virus type 1 (HSV-1) glycoprotein B (gB) is associated with cell fusion and resistance to heparin inhibition of cell fusion.
Foster TP; Melancon JM; Kousoulas KG
Virology; 2001 Aug; 287(1):18-29. PubMed ID: 11504538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
